Busulfan Tablets

It is a bifunctional alkylating agent belonging to the class of bismethyl sulfonates and is a non-specific drug for the cell cycle. When it enters the human body, the ring structure of the sulfonate group opens and destroys the structure and function of DNA by alkylating guanine in the cell's DNA. The cytotoxic effect of this product is almost entirely manifested in the inhibition of hematopoietic function, mainly manifested in the obvious inhibition of granulocyte production. The second is the inhibition of platelets and red blood cells, and the inhibition of lymphocytes is very weak.

Busulfan

It is used for chronic myeloid leukemia, and is also effective for polycythemia vera, chronic lymphocytic leukemia, and lymphoma.

Remission induction for chronic myeloid leukemia in adults: 60ug/kg/day, the maximum dose is 4mg/day, which can be given once. Maintenance therapy: The dose is usually 500ug-2mg/day. Remission induction for polycythemia vera and essential thrombocythemia: 4-6mg/day. Maintenance therapy: The dose is about half of the induction dose. The starting dose for myelofibrosis is 2-4mg/day.

Gastrointestinal reactions are mild. Main symptoms include bone marrow suppression, thrombocytopenia and bleeding. Long-term use may cause bone marrow aplasia. In addition, dizziness, flushing, cold limbs or brown-red pigmentation of the skin, hair loss, rash, etc. may occur. Occasionally, it may cause testicular atrophy, breast development in men, and amenorrhea in women. Some patients may develop pulmonary fibrosis and adrenal cortex dysfunction after long-term use.

1. Patients with acute leukemia, aplastic anemia or other hemorrhagic diseases should not use this medicine. 2. Patients with adrenal cortex insufficiency should use this medicine with caution. 3. Pregnant women should use this medicine with caution or not use it at all.

Because taking this product can increase the level of uric acid in the blood and urine, anti-gout drugs can be used for patients with a history of gout or patients whose uric acid level increases after taking this product.

Room temperature, shading, sealed.

2mg

Yingzi Maishitong (Hebi) Pharmaceutical Co., Ltd.

• Founded in:

  2003-10-09

• Address:

  Haihe Road, Hebi Economic and Technological Development Zone

• Tax NO.:

  914106007538916455

• Registered Funds:

  11.78 million yuan

• Email:

  Log in to view